In the CROWN trial, lorlatinib resulted in a 3-year PFS rate of 64% for ALK+ NSCLC patients compared to 19% for crizotinib [hazard ratio = 0.27; 95% confidence interval (CI): 0.18 to 0.39; P < 0.001]. This evidence concerns the gene ALK and non-small cell lung carcinoma.